

## **Spectrum of rhodopsin mutations in French autosomal dominant rod-cone dystrophy patients.**

Isabelle Audo, Gaël Manes, Saddek Mohand-Saïd, Anne Friedrich, Marie-Elise Lancelot, Aline Antonio, Veselina Moskova-Doumanova, Olivier Poch, Xavier Zanlonghi, Christian Hamel, et al.

► **To cite this version:**

Isabelle Audo, Gaël Manes, Saddek Mohand-Saïd, Anne Friedrich, Marie-Elise Lancelot, et al.. Spectrum of rhodopsin mutations in French autosomal dominant rod-cone dystrophy patients.. Invest Ophthalmol Vis Sci, 2010, 51 (7), pp.3687-700. <10.1167/iovs.09-4766>. <inserm-00472460>

**HAL Id: inserm-00472460**

**<http://www.hal.inserm.fr/inserm-00472460>**

Submitted on 21 Feb 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# **Spectrum of rhodopsin mutations in French autosomal dominant rod-cone dystrophy patients**

Isabelle Audo <sup>1 2 3</sup>, Gaël Manes <sup>4</sup>, Saddek Mohand-Saïd <sup>2 1</sup>, Anne Friedrich <sup>5</sup>, Marie-Elise Lancelot <sup>1</sup>, Aline Antonio <sup>1 2</sup>, Veselina Moskova-Doumanova <sup>1</sup>, Olivier Poch <sup>5</sup>, Xavier Zanlonghi <sup>6</sup>, Christian P. Hamel <sup>4 7</sup>, José-Alain Sahel <sup>1 2 3</sup>, Shomi S Bhattacharya <sup>1 3</sup>, Christina Zeitz <sup>1 \*</sup>

<sup>1</sup> Institut de la vision INSERM : U968, Université Pierre et Marie Curie - Paris VI, CNRS : UMR7210, FR

<sup>2</sup> CIC - Quinze-Vingts INSERM : CIC503, Chno Des Quinze-Vingts PARIS VI 28, Rue de Charenton 75012 PARIS,FR

<sup>3</sup> Department of Molecular Genetics Institute of Ophthalmology, London,GB

<sup>4</sup> Physiopathologie et thérapie des déficits sensoriels et moteurs INSERM : U583, IFR76, Université Montpellier II - Sciences et Techniques du Languedoc, Hopital Saint-Eloi 80, Avenue Auguste Fliche 34295 MONTPELLIER CEDEX 5,FR

<sup>5</sup> IGBMC, Institut de Génétique et de Biologie Moléculaire et Cellulaire INSERM : U964, CNRS : UMR7104, Université de Strasbourg, Parc D'Innovation 1 Rue Laurent Fries - BP 10142 67404 ILLKIRCH CEDEX,FR

<sup>6</sup> Service Exploration Fonctionnelle de la Vision Clinique Sourdis, Nantes,FR

<sup>7</sup> Centre de Référence Maladies Sensorielles Génétiques CHRU Montpellier, Hopital Gui de Chauillac, FR

\* Correspondence should be addressed to: Christina Zeitz <christina.zeitz@inserm.fr >

## **Abstract**

### **Purpose**

To identify the prevalence of rhodopsin (RHO) mutations in French patients with autosomal dominant rod-cone dystrophies (adRP).

### **Methods**

Detailed phenotypic characterization was performed including precise family history, best corrected visual acuity using the ETDRS chart, slit lamp examination, kinetic and static perimetry, full field and multifocal electroretinography (ERG), fundus autofluorescence imaging (FAF) and optical coherence tomography (OCT). For genetic diagnosis, genomic DNA of seventy-nine families was isolated by standard methods. The coding exons and flanking intronic regions of RHO were PCR amplified, purified and sequenced in the index patient.

### **Results**

Among this French adRP cohort, 16.5% revealed a RHO mutation. While three unrelated families showed each a novel missense mutation (p.Leu88Pro, p.Met207Lys and p.Gln344Pro), ten unrelated families showed recurrent previously published mutations (p.Asn15Ser, p.Leu131Pro, p.Arg135Trp, p.Ser334GlyfsX20 and p.Pro347Leu). All mutations co-segregated with the phenotype within a family and the novel mutations were not identified in a control population.

### **Conclusion**

Our studies revealed that the prevalence of RHO mutations in French adRP patients is in accordance with other studies from Europe. Most of the changes identified herein reflect recurrent mutations within which p.Pro347Leu substitution is the most prevalent. Nevertheless, almost a quarter of the changes are novel indicating that, although RHO is the first gene implicated and probably the most studied gene in RP, it is still relevant to perform mutation analysis in the coding exons of RHO to detect novel changes. Our detailed phenotype-genotype analyses in all family members available deliver the basis for therapeutic approaches in those families.

**MESH Keywords** Adolescent ; Adult ; Child ; DNA Mutational Analysis ; Electroretinography ; European Continental Ancestry Group ; genetics ; Female ; Fluorescein Angiography ; France ; epidemiology ; Genes, Dominant ; Genotype ; Humans ; Male ; Middle Aged ; Mutation ; Pedigree ; Phenotype ; Photoreceptor Cells, Vertebrate ; pathology ; Polymerase Chain Reaction ; Prevalence ; Retinitis Pigmentosa ; diagnosis ; genetics ; Rhodopsin ; genetics ; Tomography, Optical Coherence ; Visual Acuity ; Young Adult

Rod-cone dystrophies, also called retinitis pigmentosa (RP), are a clinically and genetically heterogeneous group of inherited retinal disorders primarily affecting rods with secondary cone degeneration 1. RP patients initially often complain of night blindness. This is attributed to the primarily affected rods and clinical sign of the impaired rod function. Later on, when the secondary cone dysfunctions manifests, progressive visual field constriction, abnormal color vision and loss of central vision can be observed – signs of decreasing cone function. As the disease progresses and retinal dysfunction decreases, visual impairment increases: in some cases the disease may eventually result in very severe visual impairment or even blindness. RP is the most common inherited form of severe retinal degeneration, with a frequency of about 1 in 4000 births and more than 1 million affected individuals over the world. The mode of inheritance can be

X-linked (5–15%) autosomal dominant (30–40%) or autosomal recessive (50–60%) The remaining patients represent isolated cases of which the inheritance trait can not be established 1 .

To date, 20 autosomal dominant RP (adRP) genes have been reported (<http://www.sph.uth.tmc.edu/Retnet/> ). One of the major genes underlying this disorder is rhodopsin (RHO ) coding for the light absorbing molecule that initiates the signal transmission cascade in rod photoreceptors. According to the literature, RHO mutation prevalence ranges from 0 to 50% cases of adRP in cohorts from various geographical origins, with higher numbers reported in the United States 2 –18 .

The genetic and phenotypic heterogeneity is not only found in RP in general but also specifically reflected in adRP with RHO mutations: Over 120 mutations have been identified in different sites of the gene including specific hot spots ( <http://www.sph.uth.tmc.edu/Retnet/> , <http://www.hgmd.cf.ac.uk/ac/all.php> , <http://www.retina-international.org/sci-news/rhomut.htm> ) 19 .

Certain mutations in RHO lead to diffuse rod-cone dysfunction whereas other cases are implicated in a more restricted disease that may predominate in the inferior part of the retina such as in sector RP 20 . Phenotypic classifications have been proposed to reflect this variability. In particular, Cideciyan and co-workers have distinguished two classes of disease expression with allele-specificity 21 : class A mutants show severely generalized abnormal rod function early in life with a constant rate of cone disease progression across the retina with time. Class B mutants show more restricted disease and absent or lateonset night blindness.

Other classifications have been proposed based on the underlying pathogenic mechanism involved in adRP due to RHO mutations. Mendes and co-workers classified the different types of mutations in 6 groups. Class I refers exclusively to rhodopsin mutations that fold correctly but are not transported to the outer segment. Class II, refers to mutations that misfold, are retained in the endoplasmic reticulum (ER) and cannot easily reconstitute with 11-cis -retinal. Class III refers to mutations that affect endocytosis. Class IV mutations do not affect folding per se but might affect rhodopsin stability and posttranslational modification. Similarly, Class V mutations have no obvious folding defect but show an increased activation rate for transducin. Mutants that appear to fold correctly but lead to the constitutive activation of opsin in the absence of the chromophore and in the dark constitute Class VI. Other mutations with unclear biochemical or cellular defect, or uninvestigated defect were not classified 19 .

Our comprehensive study presented herein aim to investigate in detail a French adRP cohort coming from 2 different clinical centers, namely Quinze-Vingts hospital in Paris and the Centre Hospitalier Régional in Montpellier located in the south of France. We will present the prevalence of rhodopsin mutations in this cohort and show precise phenotype-genotype correlations. Novel mutations will be analyzed on its predicted pathogenic mechanism as well as frequently mutated sites will be presented as putative candidates for therapeutic approaches.

## **METHODS**

### **Clinic**

Seventy-nine families with a provisional diagnosis of autosomal dominant rod-cone dystrophy, (adRP) were ascertained in the CIC of the Quinze-Vingts hospital, Paris (67 families) and in Montpellier (12 families). Informed consent was obtained from each patient and normal individual controls after explanation of the study and its potential outcome. The study protocol adhered to the tenets of the Declaration of Helsinki and was approved by the local ethics committees. Each patient underwent full ophthalmic examination with assessment of best corrected visual acuity using ETDRS chart, kinetic and static perimetry and colour vision using the desaturated Farnsworth Panel D-15. Fullfield and multifocal electroretinography (ERG and mfERG) were performed with DTL recording electrodes and incorporated the ISCEV Standards (Espion2 Diagnosys® for full field ERG and Veris II for Multifocal ERG) 22 , 23 . Severe rod-cone dysfunction was considered when no detectable responses were recorded. Clinical assessment was completed with Fundus Autofluorescence Imaging (FAF) and Optical Coherence Tomography (OCT) (HRAII® and Spectralis® OCT, Heidelberg Engineering, Dossenheim, Germany). At the end of clinical evaluation, patients and family members were asked to donate a blood sample for further genetic studies.

### **Mutation analysis**

Total genomic DNA was extracted from peripheral leucocytes in blood samples by standard salting out procedures 24 or according to manufacturer recommendation (Puregen Kit, Qiagen, Courtaboeuf, France). Subsequently, either genotyping or direct sequencing of RHO was performed. For genotyping 2 to 3 polymorphic microsatellite markers within or contiguous to known adRP genes (RHO, RDS, PRPF31, RP1, PRPF8, IMPDH1, PRPF3, NRL, CA4, CRX, TOPORS, PAP1, NR2E3 ) was used. Results were analysed with GeneMapper software (version 4.0, Applied Biosystems). The coding 5 exons of rhodopsin (RHO RefSeq NM000539.2) and the flanking intronic regions were amplified with oligonucleotides previously described 25 At least 125 commercially available control samples were used to validate the pathogenicity of the novel sequence variants (Human random control panel 1–3, Health Protection Agency Culture Collections, Salisbury, United Kingdom).

## RESULTS

### Mutation analysis

Thirteen index patients of the investigated 79 French autosomal dominant RP patients revealed a RHO mutation (Table 1 ). These mutations co-segregated with the phenotype when tested in family members available. Three index patients showed each a novel missense mutation, while ten index patients revealed previously described mutations in RHO (Table 1 and Figure 2a ).

- 1  
Patient CIC00218 from family 155, originating from the Southwest of France, had a novel c.263T>C mutation on exon 1 leading to a p.Leu88Pro substitution (Figures 1A and 2A )
- 2  
Patient CIC00716 of family 475, from Northern France revealed a novel mutation c.620T>A in exon 3 leading to a p.Met207Arg substitution, which segregates with an unusual restricted chorioretinal atrophy phenotype (Figure 1b ) (Audo et al., 2010, in press ).
- 3  
Patient CIC00590 from family 394, with Sephardim Jewish origins, revealed a novel mutation, c.1031A>C in exon 5, leading to a p.Gln344Pro substitution (Figure 1c and 2a ).
- 4 and 5  
Two patients from two unrelated families (PB41 and 42) from a similar region in France revealed the known c.44A>G mutation in exon 1 leading to a p.Asn15Ser exchange (Figure 1d ).
- 6  
Patient CIC00123 from family 172/96 originating from Martinique, within the French West Indies, showed a previously described heterozygous c.392T>C mutation in exon 2 leading to a p.Leu131Pro substitution (Figure 1e ).
- 7 and 8  
Two index patients CIC00364 and CIC00974 from two unrelated families 247 and 610 respectively revealed the known mutation c.403C>T in exon 2 leading to a p.Arg135Trp substitution, which co-segregated with the disease (Figure 1f ).
- 9  
Index patient 2296 from family RP827 revealed the earlier described c.998\_999insAGGC insertion leading to a predicted frameshift mutation (p.Ser334GlyfsX20), which is assumed to change the open reading frame and elongates the altered protein (Figure 1g ).
- 10–13  
Four index patients CIC00161, CIC00841, CIC00944 and CIC01125 from 4 unrelated families with origins in 4 distinct regions of France (family 119, family 546, family 598 and family 681, respectively) revealed the c.1040C>T mutation in exon 5 leading to the p.Pro347Leu substitution, which co-segregated in family members available for genetic testing (Figure 1h ).

### Prevalence of different RHO mutations in France

Together our study on autosomal dominant RP patients from France showed that 16.5% revealed novel or known RHO mutations. Mutations locations revealed no specific hot spots since they involved all exons. However, three mutations occurred at least in two families indicating that the p.Asn15Ser, p.Arg135Trp and the p.Pro347Leu substitutions in RHO are frequent causes of RP in this population.

### Phenotypic characteristics of patients with RHO mutation

Thirty affected subjects, between age 8 and 62, from the 13 families found with RHO mutation underwent complete clinical examination. Their phenotypic details are summarized in Table 2 . The group of patients reported here shows 3 distinct phenotypes and resemble either class A or B mutants from the classification proposed by Cideciyan and co-workers 21 :

- **a generalized rod-cone dysfunction** observed in patients carrying mutations (p.Leu88Pro, p.Leu131Pro, p.Arg135Trp, p.Ser334GlyfsX20, p.Gln344Pro, p.Pro347Leu), which resemble the class A mutants.
- **a sector RP** associated with the p. Asn15Ser mutation and

• **a restricted chorioretinal dystrophy predominant at the posterior pole** associated with the p.Met207Lys substitution. Due to the more restricted phenotype, we classified the two latter mutations as class B mutations.

In **generalized forms**, symptoms are classical for RP with no obvious phenotype/genotype differences and are dominated by night blindness, from early childhood, progressive peripheral visual field constriction and late photophobia. Age at time of diagnosis varies from 8 to 49 with a majority within the teenage years, earlier than restricted diseases. Central vision ranges from 20/20 to 20/400. It decreases with age, after peripheral visual field impairment, and is usually relatively conserved up to the 5<sup>th</sup> decade. However, in 8/21 patients, atrophic changes within the macula occur after the mid-twenties and compromised further central vision. Some degree of cataract or intraocular lens is present as early as 34 in 11/21 patients. Fundus examination, shows in most patients classical RPE changes in the periphery with intraretinal pigment migrations, sign of photoreceptor cell death, increasing with age. White dots are present in 5 patients who are 43 or younger associated with three genotypes are in our series: p.Leu131Pro, p.Gln344Pro and p.Pro347Leu. OCT findings are summarized in Table 2. There was no correlation between OCT abnormalities and genotype. Cystoid Macular Edema (CME) is present in 4/30 patients in association with 4 different genotypes. A perifoveal ring of hyper-autofluorescence is present 13/18 patients for whom fundus autofluorescence imaging has been performed. Absence of this ring is associated with irregular loss of autofluorescence within the macula in relation with atrophic changes (Figure 3). ERG responses are usually undetectable for both scotopic and photopic recordings after 30 or show only residual photopic Flicker responses. When ERGs are detectable, in younger patients, they usually show more decreased amplitudes for scotopic than photopic responses with implicit time shift, consistent with generalized rod-cone dysfunction.

**Sector RP** was seen in 2 families (PB41 and PB42) carrying the same p.Asn15Ser change. Five patients, from age 28 to 60, underwent full ophthalmic examination. Night blindness is an inconstant sign in these subjects who all retain a normal central vision with inferior peripheral field defect correlated with fundus abnormalities. ERG responses show decreased scotopic responses with additional photopic abnormalities in some patients. There is however no implicit time shift consistent with a restricted rod-cone dysfunction.

One additional family, F475 with a novel p.Met207Arg, shows also restricted chorioretinal degeneration. Phenotype-genotype correlations are described in more details elsewhere (Audo et al., 2010, in press). Briefly, onset of symptoms appears in the fourth decade in this family with moderate night blindness and asymmetric visual loss. Affected family members show patchy areas of chorioretinal atrophy within the posterior pole (Figure 3) with decreased ERG response amplitudes for both scotopic and photopic responses and no implicit time shift consistent with restricted disease.

## DISCUSSION

The current study reports mutation spectrum on the rhodopsin gene in a cohort of patients from 2 major French centres and further outlines phenotypic variability associated with rhodopsin mutation showing both, generalized or sectorial retinal degeneration. To the best of our knowledge to date only two studies on RHO mutations in a French cohort were published: One describing the prevalence of RHO mutations in Southern France and the other reported on the identification of 5 new mutations with no information on prevalence and ethnic origin 13, 26.

The overall prevalence of RHO mutations in our cohort is 16.5%. This is consistent with previous reports on European cohorts including Spain (20%)<sup>10</sup>, Germany (16%)<sup>11</sup>, Italy (16%)<sup>12</sup> and Southern France (10%).<sup>13</sup> This is higher than reports from China (2–7%)<sup>14</sup>, 15, 27, Japan (0–6%)<sup>16</sup> India (0–2%)<sup>17</sup> and South-Africa (7%)<sup>18</sup>. Studies from the UK and Norway revealed higher numbers with 30–50%<sup>8, 9, 28</sup>. However, the studied cohorts were small (12–20 families) and thus these results must be validated in larger cohorts. In the US population RHO mutations were shown to account for up to 30% of adRP<sup>3–7</sup>. The prevalence of the p.Pro23His mutation in the US has been reported as high as 12% of adRP due to a founder effect from a common British ancestor<sup>29</sup>. This mutation has never been found in European cohorts of adRP<sup>30</sup>, including the current report, nor in Asian cohorts<sup>31, 32</sup>, which would account for differences in the overall RHO mutation prevalence between the American population and reports from other populations.

Three novel changes were identified in the current study: p.Leu88Pro, p.Met207Lys and Gln344Pro.

The p.Leu88Pro substitution leads to a severe generalized rod-cone dystrophy phenotype in the patients. Disease-causing mutations have already been reported for the surrounding residues (namely p.Val87Asp and p.Gly89Asp) and misfolding has been hypothesised as a pathogenic mechanism<sup>4, 33</sup>. The Leucine in 88 is located within the alpha helix of the second transmembrane domain of rhodopsin. The residue at this position is not invariant among Metazoan organism (Figure 2b), but shows always hydrophobic characteristics, necessary for the maintenance of this alpha helix. The substitution of the leucine by a proline would induce a kink in the helix and destabilize the protein through rhodopsin misfolding. This would classify the p.Leu88Pro within class II after Mendes and colleagues<sup>19</sup>.

The novel p.Met207Arg substitution was associated with unusual chorioretinal atrophy. Mutation consequences are discussed elsewhere (Audo et al., 2010, in press) and would suggest a change in sterical constraints within the retinal binding pocket.

The c.1031A>C change in exon 5 leading to a p.Gln344Pro substitution was associated with a severe generalized rod-cone dystrophy. Gln at this position is evolutionary highly conserved (Figure 2b). It is located in the C-term external loop and it is unlikely that mutations in this residue would induce a misfolding. This would classify our novel change p.Gln344Pro in class I after Mendes and colleagues 19. Previously a c.1030C>T change leading to a p.Gln344Stop was associated with normal phototransduction function but with mislocalization 34. Furthermore, Tai and co-workers identified the direct interaction between a dynein light-chain subunit and the C-terminus of rhodopsin, which is important for the correct protein transport of post-Golgi rhodopsin-containing vesicles along the microtubules up to the outer segment 35. Different C-terminal mutations were unable to interact with this domain and thus led to a trafficking defect. A similar mechanism can be advocated for the novel reported change p.Gln344Pro.

The 10 other families identified with RHO mutation showed already described changes. The p.Asn15Ser mutation was identified in two different families from a similar region of France and thus represents probably a founder effect. Asn15 represent one of the important N-glycosylation sites of RHO. Thus the underlying pathogenic mechanism of the p.Asn15Ser was proposed to be trafficking defect 36.

The p.Leu131Pro mutation was identified in a large family from Martinique with typical diffuse rod-cone dystrophy, type A from Cideciyan and co-workers 21. This amino-acid substitution is assumed to lead to misfolding 37. Since this exchange has also been previously reported in another study from France 26, it may represent a major mutation in the affected French population.

The p.Arg135Trp was found in two unrelated families and was associated with typical severe diffuse rod-cone dystrophy, type A from Cideciyan and co-workers 21 as previously reported 38 39. Of notes, none of the examined patients in these 2 families demonstrated the white dots previously described in association with this genotype 39, 40. An explanation would be that the examined patients were either too young or too old to exhibit this distinct feature since, Oh and co-worker have reported the transient nature of these white dots appearing in the second decades of life then fading to leave place to RPE atrophy and bone spicules. It is also noteworthy that these white dots, which are located at the level of the RPE, are not specific of the p.Arg135Trp mutation since it was also seen in association with other RHO mutations in our series and may represent a non-specific sign of photoreceptor degeneration (see table 2 on clinical data).

The p.Pro347Leu mutation was the most prevalent, found in 4 families which would represent 5% of our adRP families. This mutation has also been reported in other populations 8, 10, 29, 32, 41. Although the 4 families studied herein were unrelated and from different geographical origin, a founder effect cannot be excluded. Haplotype analysis was not performed for this study. However, the gene location is a known hotspot through a higher probability of C>T transition due to a CpG sequence 3 and 6 disease causing amino-acid substitutions have reported at this location (see <http://www.retina-international.org/sci-news/rhomut.htm>). Again, it was suggested that for these substitutions a trafficking defect represent the pathogenic mechanism. Patients carrying the p.Pro347Leu mutation have a comparable phenotype as patients carrying the p.Gln344Pro and p.Ser334GlnfsX20 changes, all being located at the C-terminus, with early onset-night blindness, and generalized severe rod-cone dystrophy with loss of central vision in the 5<sup>th</sup> decades. The severity of the disease associated with C-terminal changes within the cytoplasmic domain is well documented in the literature 42–44 showing a worse prognosis compared in particular to the p.Pro23His mutation located in the N-terminal intradiscal/extracellular portion of the protein 43, 44. Our cohort in whom genotype-phenotype correlation was performed is still too small to judge the severity associated with a specific mutation but recurrent follow-up will further address this question.

One additional criterion that will need to be further precisely evaluated is the course of macular involvement: perifoveal and foveal atrophy is not uncommon in our series (see table 2 with clinical details) as well as cystoid macular edema which was present in 4/31 patients with no genotype-specificity. These macular changes are responsible for decreased central vision and their prevention should be the major target of future therapeutic interventions.

Further longitudinal studies will precise the course of the disease for each genotype and will help identifying suitable markers and therapeutic windows for photoreceptor rescue, gene replacement or cell based therapies.

## Acknowledgements:

The authors are grateful to patients and family members described in this study, to Thierry Léveillard, Dominique Santiard-Baron, Christine Chaumeil and clinical staff for their help in DNA collection and clinical staff from the Centre National de Référence Maladies Rares in Montpellier, Béatrice Bocquet and Delphine Coustes-Chazallette for their help with DNA collection, Gabor Mátyás, Institute of Medical Genetics in Zurich for providing the purification and sequencing protocol used herein. The project was financially supported by Foundation Fighting Blindness (I.A.), ANR (SS.B), Foundation Voir et Entendre and BQR, Université Pierre et Marie Curie<sup>6</sup> (C.Z), PHRC national adRP (C.H).

## Footnotes:

Data regarding family 475 have been presented as a poster at the ARVO 2009 meeting and are also published elsewhere (Audo et al. 2010, in press).

## References:


1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. *Lancet*. 2006; 368: 1795 - 1809
2. Dryja TP, McEvoy JA, McGee TL, Berson EL. Novel rhodopsin mutations Gly114Val and Gln184Pro in dominant retinitis pigmentosa. *Invest Ophthalmol Vis Sci*. 2000; 41: 3124 - 3127
3. Dryja TP, Hahn LB, Cowley GS, McGee TL, Berson EL. Mutation spectrum of the rhodopsin gene among patients with autosomal dominant retinitis pigmentosa. *Proc Natl Acad Sci U S A*. 1991; 88: 9370 - 9374
4. Sung CH, Davenport CM, Hennessey JC. Rhodopsin mutations in autosomal dominant retinitis pigmentosa. *Proc Natl Acad Sci U S A*. 1991; 88: 6481 - 6485
5. Macke JP, Davenport CM, Jacobson SG. Identification of novel rhodopsin mutations responsible for retinitis pigmentosa: implications for the structure and function of rhodopsin. *Am J Hum Genet*. 1993; 53: 80 - 89
6. Sohocki MM, Daiger SP, Bowne SJ. Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. *Hum Mutat*. 2001; 17: 42 - 51
7. Sullivan LS, Bowne SJ, Birch DG. Prevalence of disease-causing mutations in families with autosomal dominant retinitis pigmentosa: a screen of known genes in 200 families. *Invest Ophthalmol Vis Sci*. 2006; 47: 3052 - 3064
8. Inglehearn CF, Keen TJ, Bashir R. A completed screen for mutations of the rhodopsin gene in a panel of patients with autosomal dominant retinitis pigmentosa. *Hum Mol Genet*. 1992; 1: 41 - 45
9. Grondahl J, Riise R, Heiberg A, Leren T, Christoffersen T, Bragadottir R. Autosomal dominant retinitis pigmentosa in Norway: a 20-year clinical follow-up study with molecular genetic analysis. Two novel rhodopsin mutations: 1003delG and I179F. *Acta Ophthalmol Scand*. 2007; 85: 287 - 297
10. Milla E, Maseras M, Martinez-Gimeno M. Genetic and molecular characterization of 148 patients with autosomal dominant retinitis pigmentosa (ADRP). *Arch Soc Esp Ophthalmol*. 2002; 77: 481 - 484
11. Bunge S, Wedemann H, David D. Molecular analysis and genetic mapping of the rhodopsin gene in families with autosomal dominant retinitis pigmentosa. *Genomics*. 1993; 17: 230 - 233
12. Ziviello C, Simonelli F, Testa F. Molecular genetics of autosomal dominant retinitis pigmentosa (ADRP): a comprehensive study of 43 Italian families. *J Med Genet*. 2005; 42: e47 -
13. Bareil C, Hamel C, Pallares-Ruiz N, Arnaud B, Demaille J, Claustres M. Molecular analysis of the rhodopsin gene in southern France: identification of the first duplication responsible for retinitis pigmentosa, c. 998999ins4. *Ophthalmic Genet*. 1999; 20: 173 - 182
14. Zhao K, Xiong S, Wang L, Wang L, Cui Y, Wang Q. Novel rhodopsin mutation in a Chinese family with autosomal dominant retinitis pigmentosa. *Ophthalmic Genet*. 2001; 22: 155 - 162
15. Zhang XL, Liu M, Meng XH. A complete screen for mutations of the rhodopsin gene in a panel of Chinese patients with autosomal dominant retinitis pigmentosa. *Chin Med Sci J*. 2005; 20: 30 - 34
16. Ando Y, Ohmori M, Ohtake H. Mutation screening and haplotype analysis of the rhodopsin gene locus in Japanese patients with retinitis pigmentosa. *Mol Vis*. 2007; 13: 1038 - 1044
17. Gandra M, Anandula V, Authiappan V. Retinitis pigmentosa: mutation analysis of RHO, PRPF31, RP1, and IMPDH1 genes in patients from India. *Mol Vis*. 2008; 14: 1105 - 1113
18. Roberts L, Ramesar R, Greenberg J. Low frequency of rhodopsin mutations in South African patients with autosomal dominant retinitis pigmentosa. *Clin Genet*. 2000; 58: 77 - 78
19. Mendes HF, van der Spuy J, Chapple JP, Cheetham ME. Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. *Trends Mol Med*. 2005; 11: 177 - 185
20. Heckenlively JR, Rodriguez JA, Daiger SP. Autosomal dominant sectoral retinitis pigmentosa. Two families with transversion mutation in codon 23 of rhodopsin. *Arch Ophthalmol*. 1991; 109: 84 - 91
21. Cideciyan AV, Hood DC, Huang Y. Disease sequence from mutant rhodopsin allele to rod and cone photoreceptor degeneration in man. *Proc Natl Acad Sci U S A*. 1998; 95: 7103 - 7108
22. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M. ISCEV Standard for full-field clinical electroretinography (2008 update). *Doc Ophthalmol*. 2009; 118: 69 - 77
23. Hood DC, Bach M, Brigell M. ISCEV guidelines for clinical multifocal electroretinography (2007 edition). *Doc Ophthalmol*. 2008; 116: 1 - 11
24. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res*. 1988; 16: 1215 -
25. Neidhardt J, Barthelmes D, Farahmand F, Fleischhauer JC, Berger W. Different amino acid substitutions at the same position in rhodopsin lead to distinct phenotypes. *Invest Ophthalmol Vis Sci*. 2006; 47: 1630 - 1635
26. Souied E, Gerber S, Rozet JM. Five novel missense mutations of the rhodopsin gene in autosomal dominant retinitis pigmentosa. *Hum Mol Genet*. 1994; 3: 1433 - 1434
27. Chan WM, Yeung KY, Pang CP. Rhodopsin mutations in Chinese patients with retinitis pigmentosa. *Br J Ophthalmol*. 2001; 85: 1046 - 1048
28. Inglehearn CF, Tarttelin EE, Plant C. A linkage survey of 20 dominant retinitis pigmentosa families: frequencies of the nine known loci and evidence for further heterogeneity. *J Med Genet*. 1998; 35: 1 - 5
29. Dryja TP, McGee TL, Hahn LB. Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. *N Engl J Med*. 1990; 323: 1302 - 1307
30. Farrar GJ, Kenna P, Redmond R. Autosomal dominant retinitis pigmentosa: absence of the rhodopsin proline----histidine substitution (codon 23) in pedigrees from Europe. *Am J Hum Genet*. 1990; 47: 941 - 945
31. Nakazawa M, Kikawa-Araki E, Shiono T, Tamai M. Analysis of rhodopsin gene in patients with retinitis pigmentosa using allele-specific polymerase chain reaction. *Jpn J Ophthalmol*. 1991; 35: 386 - 393
32. Fujiki K, Hotta Y, Hayakawa M. Point mutations of rhodopsin gene found in Japanese families with autosomal dominant retinitis pigmentosa (ADRP). *Jpn J Hum Genet*. 1992; 37: 125 - 132
33. Sung CH, Schneider BG, Agarwal N, Papermaster DS, Nathans J. Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. *Proc Natl Acad Sci U S A*. 1991; 88: 8840 - 8844
34. Sung CH, Makino C, Baylor D, Nathans J. A rhodopsin gene mutation responsible for autosomal dominant retinitis pigmentosa results in a protein that is defective in localization to the photoreceptor outer segment. *J Neurosci*. 1994; 14: 5818 - 5833
35. Tai AW, Chuang JZ, Bode C, Wolfrum U, Sung CH. Rhodopsin's carboxy-terminal cytoplasmic tail acts as a membrane receptor for cytoplasmic dynein by binding to the dynein light chain Tctex-1. *Cell*. 1999; 97: 877 - 887
36. Kranich H, Bartkowski S, Denton MJ. Autosomal dominant 'sector' retinitis pigmentosa due to a point mutation predicting an Asn-15-Ser substitution of rhodopsin. *Hum Mol Genet*. 1993; 2: 813 - 814
37. Fuchs S, Kranich H, Denton MJ. Three novel rhodopsin mutations (C110F, L131P, A164V) in patients with autosomal dominant retinitis pigmentosa. *Hum Mol Genet*. 1994; 3: 1203 -
38. Pannarale MR, Grammatico B, Iannaccone A. Autosomal-dominant retinitis pigmentosa associated with an Arg-135-Trp point mutation of the rhodopsin gene. Clinical features and longitudinal observations. *Ophthalmology*. 1996; 103: 1443 - 1452
39. Oh KT, Oh DM, Weleber RG. Genotype-phenotype correlation in a family with Arg135Leu rhodopsin retinitis pigmentosa. *Br J Ophthalmol*. 2004; 88: 1533 - 1537
40. Souied E, Soubrane G, Benlian P. Retinitis punctata albescens associated with the Arg135Trp mutation in the rhodopsin gene. *Am J Ophthalmol*. 1996; 121: 19 - 25
41. Greenberg J, Franz T, Goliath R, Ramesar R. A photoreceptor gene mutation in an indigenous black African family with retinitis pigmentosa identified using a rapid screening approach for common rhodopsin mutations. *S Afr Med J*. 1999; 89: 877 - 878

- 42 . Berson EL , Rosner B , Sandberg MA , Weigel-DiFranco C , Dryja TP . Ocular findings in patients with autosomal dominant retinitis pigmentosa and rhodopsin, proline-347-leucine . Am J Ophthalmol . 1991 ; 111 : 614 - 623
- 43 . Sandberg MA , Weigel-DiFranco C , Dryja TP , Berson EL . Clinical expression correlates with location of rhodopsin mutation in dominant retinitis pigmentosa . Invest Ophthalmol Vis Sci . 1995 ; 36 : 1934 - 1942
- 44 . Oh KT , Longmuir R , Oh DM . Comparison of the clinical expression of retinitis pigmentosa associated with rhodopsin mutations at codon 347 and codon 23 . Am J Ophthalmol . 2003 ; 136 : 306 - 313

**Figure 1**


Pedigrees of adRP patients with RHO mutations and co-segregation in available family members. Filled symbols represent affected and unfilled unaffected persons. Squares indicate males, circles females. Arrows reflect the index patients.

**Figure 1a**



**Figure 1b**

**Family 475**



**Figure 1c**

**Fam 394**






Figure 1d

Fam PB41




Figure 1d

Fam PB42




Figure 1e

Fam 172/96




Figure 1f




Figure 1f

Fam 610




Figure 1g

Fam RP827




Figure 1h

Fam 119





Figure 1h

Fam 546



Fam 598




Figure 1h

Fam 681





Figure 2

(a). Electropherograms of novel RHO mutations highlighted by an arrow. (b) Multiple amino acid sequence alignments of different species of novel mutated residues (depicted in green). Amino acid substitutions are highlighted in red. The position of the respective amino acids is shown in black numbers.

Figure 2a




# Figure 2b

	88	344
	P	P
Human	DLFMV <sup>P</sup> LG <sup>P</sup> GFTS	KTETSQVAPA*
Rhesus	DLFMV <sup>P</sup> FGGFTT	KTETSQVAPA*
Tarsier	DLFMV <sup>P</sup> FGGFTS	KTETSQVAPA*
Mouse	DLFMV <sup>P</sup> FGGFTT	KTETSQVAPA*
Dog	DLFMV <sup>P</sup> FGGFTT	KTETSQVAPA*
Elephant	NHFMV <sup>P</sup> FGGFTT	-----
Opossum	DLFMV <sup>P</sup> FGGFTM	KTETSQVAPA*
Platypus	NHFMV <sup>P</sup> LG <sup>P</sup> GFTT	KTETSQVSPA*
Chicken	DLFMV <sup>P</sup> GRFTT	KTETSQVSPA*
Lizard	NLFMV <sup>P</sup> LMGFTT	KTETSQVSPA*
X_tropicalis	NHFMV <sup>P</sup> LCGFTV	KTESSQVSPA*
Stickleback	DLFMV <sup>P</sup> LG <sup>P</sup> GFTT	KTQSSQVAPA*

**Figure 3**

Fundus and autofluorescence pictures of 3 index patients with distinct adRP phenotypes (diffuse, sector RP and restricted chorioretinal atrophy)



**Table 1**

Novel and known RHO mutations in the French cohort.

Index (family)	Exon	Nucleotide Exchange	Protein Effect	Publication
2810 (PB41) 2923 (PB42)	1	c.44A>G	p.Asn15Ser	36
CIC00218 (F155)	1	c.263T>C	p.Leu88Pro	novel
CIC00123 (F172/96)	2	c.392T>C	p.Leu131Pro	26
CIC00364 (F247) CIC00974 (F610)	2	c.403C>T	p.Arg135Trp	4
CIC00716 (F475)	3	c. 620T>A	p.Met207Lys	novel (phenotypegenotype correlation published Audo et al., in press)
2296 (RP827)	5	c.998_999insAGGC	p.Ser334GlyfsX20	13
CIC00590 (F394)	5	c.1031A>C	p.Gln344Pro	novel
CIC00161 (F119) CIC00841 (F546) CIC00944 (F598) CIC01125 (F681)	5	c.1040C>T	p.Pro347Leu	29

**Table 2**

Clinical features of affected members from families with autosomal dominant retinitis pigmentosa (adRP) due to RHO mutations.

Family and RHO mutation	Patient Sex	Age of diagnos	Symptoms	Age at exam	BCVA OD/OS	Cataract	Fundus	OCT	VF	ERG ISCEV standards
	2752 III.12	F	Mild night blindness	39	20/20 20/20	-	Bone spicules in Lower sector	Normal foveal lamination	Central scotoma (15° Isoptre V4 60°N, 70°T	50% of normal value for scotopic responses 60% of normal value for photopic responses No implicit time shift
<b>Family PB41</b> <b>c.44A&gt;G</b> <b>p.15Asn&gt;Ser</b>	2808 II.2	F	Night blindness	59	20/20 + 2.50 (- 1.25; 170°) 20/20 + 2.00 (- 0.50; 50°)	-	Bone spicules in Lower sector	Normal foveal lamination	Isoptre V4 65°N, 70°T	20% of normal value for scotopic responses 35% of normal value for photopic responses No implicit time shift
	2929 II.4	F	No night blindness	60	20/25 + 3.25 (- 1.00; 144°) 20/25 + 2.75 (- 0.50; 10°)	-	Bone spicules in Lower sector	Normal foveal lamination	Isoptre V4 80°N, 70°T	30% of normal value for scotopic responses Photopic 30Hz ERG slightly reduced No implicit time shift
<b>Family PB42</b> <b>c.44A&gt;G</b>	2927 II.8	M	30 PVFI at 30 No night blindness	52	20/20 + 2.50 (- 2.75; 20°)	-	Bone spicules in lower sector Epiretinal membrane OD/OS	Normal foveal lamination	Isoptre V4 80°N, 90°T	30% of normal value for scotopic responses

<b>p.15Asn&gt;Ser</b>						20/20 + 2.75 (- 2.50; 170 °)						80% of normal value for photopic responses No implicit time shift
	2938 III.12	M		Mild photophobia No night blindness	28	20/20 - 0.25 (- 0.50; 15°)	-	Bone spicules in Lower sector	Normal foveal lamination	Normal		Normal scotopic responses Photopic 30Hz ERG slightly reduced No implicit time shift
<b>Family 155 c.263T&gt;C p.Leu88Pro novel</b>	CIC 00218	M	15	Night blindness since childhood photophobia at age 59 followed by progressive loss of central vision	62	20/63 20/80	IOL at age 48	bone spicules 360° some areas of central atrophy	Foveal thinning	Isoptre V4 20 ° central ODS		Not detectable
	CIC 00123	M	10	Night blindness since childhood	27	20/32 + 1.25(- 1.25)85° 20/32 +1( -1)90°	-	bone spicules 360° some areas of central atrophy, few white dots	Normal foveal lamination	Isoptre V4 OD 15° central OS<10°		Not detectable
	CIC 00249	F	30	Night blindness since childhood progressive decreased vision and photophobia	56	20/400 + 3.505(- 1.75)90° 20/500 + 3(- 1.50)90°	+	bone spicules 360° some areas of central, atrophy, no ring on AF	Foveal thinning	Isoptre III4 20° central ODS		Not detectable
<b>Family 96/172 c.392T&gt;C p.Leu131Pro</b>	CIC 00799	F	Teens	Night blindness since childhood	31	20/32 -1( -1)50° 20/32 -1( - 1.25)135°	-	Few peripheral RPE changes 360°, white dots, small perifoveal ring of hyperAF	Normal foveal lamination	Isoptre II4 110° horizontally and 90° vertically		No responses detectable in scotopic conditions, some residual flicker responses
	CIC 00500	F	Teens	Night blindness since childhood	43	20/40 + 0.25(- 0.75)120° 20/40 +0( -1)60°	+	bone spicules 360° some areas of central atrophy, white dots, small perifoveal ring of hyperAF	Normal foveal lamination	Isoptre III4 60° horizontally and 30° vertically		Not detectable
	CIC 00501	M	28	Night blindness since childhood	51	20/40 + 0.75(- 0.25)95 20/40 pl( -1.25)90°	-	bone spicules 360° some areas of central atrophy, no ring on AF	Foveal thinning	Isoptre V4 20 °		Not detectable
<b>Family 247 c.403C&gt;T p.Arg135Trp</b>	CIC 00364	F		Night blindness since childhood	52	20/40 + 3.75(- 0.25)35° 20/63 + 5.75(- 1)130°	+	bone spicules 360° some areas of central atrophy, no ring on AF	Foveal thinning	Isoptre III4 30°		Not detectable

<b>Family 610</b> <b>c.403C&gt;T</b> <b>p.Arg135Trp</b>	CIC 00974	M	10	Night blindness	37	20/40 -8(-2.75)0° 20/40 -8(-2.25)175°	-	Peripheral RPE/choroidal atrophy with bone spicules 360°, small perifoveal ring of hyperAF	Foveal thinning	Isoptre III4 170° horizontal x100° vertical	Not detectable
	CIC 00976	F	8	Night blindness	8	20/63 -2(-3.25)0° 20/40 +0.75(-2.25)180°	-	Nearly normal fundus, Perifoveal ring of hyperAF	Normal foveal lamination	Isoptre III4 140° horizontal; 100° vertical	Both scotopic and photopic amplitudes reduction *
	CIC 00977	M	10	Night blindness	11	20/20 +0.25(-2.75)5° 20/20 +0.25(-2.50)170°	-	Few RPE changes with no bone spicules, Bilateral CME, Perifoveal ring of hyperAF	CME	Isoptre III4 140° horizontal X120° vertical	Scotopic responses 10% of normal Photopic responses 50% normal Both amplitude reduction and implicit time shift
	CIC 00716	M	23	None	23	20/13 0(-1)160° 20/15 0(-1.50)15°	-	Preserved macula besides some perifoveolar RPE clumps; Moderate salt and pepper appearance of retinal periphery	Normal foveal lamination	Normal	Scotopic response amplitudes 80% of normal, normal photopic responses, no implicit time shift
<b>Family 475</b> <b>c.620T&gt;A</b> <b>p.Met207Lys</b>	CIC 00715	F	38	Decreased VA Some degree of night vision disturbances	46	20/25 +1(-0.50)160° HM	-	Patchy chorioretinal atrophy with some RPE clumps in posterior pole and mid periphery No pale disc and no narrowing of blood vessels salt and pepper aspect in retinal periphery; no bone spicules	OD normal foveal lamination OS foveal thinning	OD normal OS normal peripheral isoptre	65% of normal for scotopic response amplitudes and 90% for scotopic responses; No implicit time shift
	CIC 00717	F	40	Night blindness since age 40 Decreased VA	58	20/200 +1.75(-0.50)20° 20/25 +2.25(-0.50)140°	+	Patchy chorioretinal atrophy with some RPE clumps in posterior pole and mid periphery No pale disc and no narrowing of blood vessels, salt and pepper aspect in retinal periphery; no bone spicules	OD foveal thinning OS normal foveal lamination	Normal peripheral isoptre	Not performed
	CIC 02599	F	26	None	26	20/15 ODS with no correction	-	Normal aspect of posterior poles besides some perifoveolar RPE clumps and one small area of atrophy; Moderate salt and pepper appearance of retinal periphery	Normal foveal lamination	normal	Not performed
	2296 V.8	M	13	Night blindness at early childhood PVFI at 13 Intense photophobia	34	20/40 +5.50 (-0.50; 165°) 20/30 +5.00 (-0.50; 170°)	+	Bones spicules 360° CME	CME	15°	Not detectable
	2327 V.6	F	11	Night blindness at 11 PVFI at 20 Photophobia at 25	38	20/100 +5.00	+	Bones spicules 360° Foveal photoreceptor loss	Foveal thinning	15°	Not detectable except for residual 30 Hz flicker ERG



<b>Family RP827</b> <b>c.998_999insAGGC</b> <b>p.Ser333GlyfsX22</b>	2379	F	childhood	Night blindness since early childhood Photophobia at 5	45	20/400 + 6.00 (- 0.75; 60°) 20/30 (- 2.00; 90°) 20/40 (- 1.25; 105°)	+	Bones spicules 360° small Perifoveal ring of hyperAF	Foveal thinning	20°	Not detectable
	2324	M	50	Night blindness at early childhood PVFI at 25 Photophobia	60	20/400 + 1.50 (- 1.00; 95°) 20/200 + 2.00 (- 1.00; 85°)	IOL	Bones spicules 360°	Foveal thinning	10°	Not detectable except for residual 30 Hz flicker ERG
	CIC 00590	F	32	Night blindness since age 4 PVFI since age 19	53	20/125 - 1.50(- 1)35° 20/200 - 1.25(- 1)150°	IOL at 48	bone spicules 360°, no ring on AF, perifoveal atrophy	Foveal thinning	20°	Not detectable
<b>Family 394</b> <b>c.1031A&gt;C</b> <b>p.Gln344Pro, novel</b>	CIC 00592	H	13	Moderate night blindness	13	20/25 + 1.5(- 1.75)170° 20/32 +2(- - 2.75)175°	-	peripheral RPE changes 360° with white dots, Perifoveal ring of hyperAF	Normal foveal lamination	normal	Scotopic responses 10% of normal Photopic responses 80% normal Both amplitude reduction and implicit time shift
<b>Family 119</b> <b>c.1040C&gt;T</b> <b>p.Pro347Leu</b>	CIC 00161	H	11	Night blindness	42	20/32 plano(- 1)90° 20/25 plano(- 0.50)80°	-	Bone spicules 360°, Perifoveal ring of hyperAF	Normal foveal lamination	20°	Not detectable
<b>Family 546</b> <b>c.1040C&gt;T</b> <b>p.Pro347Leu</b>	CIC 00841	H	Teens	Night blindness since early childhood, PVFI at 25, recent photophobia	42	20/40 0(- 1)115° 20/63 -1(- 0.25)15°	+	bone spicules 360° White dots Bilateral CME, small perifoveal ring of hyperAF	CME	Isoptre III4 20°	Not detectable
	CIC 00944	F	10	Night blindness	14	20/20 +2(- 1.25)5° 20/20+ 1.5(- 05)10°	-	Some peripheral RPE changes over 360°, CME, Perifoveal ring of hyperAF	CME	normal	Scotopic responses 10% of normal Photopic responses 80% normal Both amplitude reduction and implicit time shift
<b>Family 598</b> <b>c.1040C&gt;T</b> <b>p.Pro347Leu</b>	CIC 00945	F	9	Night blindness	43	20/32 + 3.5(- 1.25)10°	-	bone spicules 360°, no ring on AF	Foveal thinning	20°	Not detectable

<b>Family 681</b> <b>c.1040C&gt;T</b> <b>p.Pro347Leu</b>	CIC 01125	F	49	Night blindness	56	20/32 + 3.75(- 0.75)5° 20/400 + 1.50(- 0.75)20° 20/200 + 3.25(- 0.75)10°	OD IOL OS +	Few bone spicules 360° some areas of central atrophy, incomplete perifoveal ring of hyperAF	Foveal thinning	Isoptre III4 40°	Not detectable
	CIC 01126	F	29	Night blindness	36	20/20 20/20	-	Few bone spicules 360° Perifoveal ring of hyperAF	Normal foveal lamination	Isoptre III4: 150° horizontally X 60° vertically	No detectable scotopic responses Some residual flicker responses

PVFI = Peripheral Visual Field Impairment, VF = Visual Field, IOL = Intraocular lens, BCVA: Best Corrected Visual Acuity, OD/OS: Right eye/Left eye, RPE: Retinal pigment epithelium, HM: Hand Motion; CME: Cystoid Macular Edema;

\* ERG performed with skin electrodes which precluded us to have a precise quantification of abnormalities, AF: autofluoresce., OCT: Optical Coherence Tomography.